New quality assurance program integrating "modern radiotherapy" within the German Hodgkin Study Group.
BACKGROUND
Field design changed substantially from extended-field RT (EF-RT) to involved-field RT (IF-RT) and now to involved-node RT (IN-RT) and involved-site RT (IS-RT) as well as treatment techniques in radiotherapy (RT) of Hodgkin's lymphoma (HL). The purpose of this article is to demonstrate the establishment of a quality assurance program (QAP) including modern RT techniques and field designs within the German Hodgkin Study Group (GHSG).


METHODS
In the era of modern conformal RT, this QAP had to be fundamentally adapted and a new evaluation process has been intensively discussed by the radiotherapeutic expert panel of the GHSG.


RESULTS
The expert panel developed guidelines and criteria to analyse "modern" field designs and treatment techniques. This work is based on a dataset of 11 patients treated within the sixth study generation (HD16-17).


CONCLUSIONS
To develop a QAP of "modern RT", the expert panel defined criteria for analysing current RT procedures. The consensus of a modified QAP in ongoing and future trials is presented. With this schedule, the QAP of the GHSG could serve as a model for other study groups.
Department of Radiation Oncology, University of Muenster, Albert-Schweitzer Campus 1, Gebäude 1 A, 48419, Muenster, Germany.
J
J
Kriz
Department of Radiation Oncology, University of Cologne, Köln, Deutschland.
C
C
Baues
Department of Radiation Oncology, University of Marburg, Marburg, Deutschland.
R
R
Engenhart-Cabillic
Department of Radiation Oncology, University of Muenster, Albert-Schweitzer Campus 1, Gebäude 1 A, 48419, Muenster, Germany.
U
U
Haverkamp
Department of Radiation Oncology, University of Heidelberg, Heidelberg, Deutschland.
K
K
Herfarth
Department of Radiation Oncology, University of Innsbruck, Innsbruck, Deutschland.
P
P
Lukas
Department of Radiation Oncology, University of Mainz, Mainz, Deutschland.
H
H
Schmidberger
Department of Radiation Oncology, University of Cologne, Köln, Deutschland.
S
S
Marnitz-Schulze
Department of Internal Medicine, University of Cologne, Köln, Deutschland.
M
M
Fuchs
Department of Internal Medicine, University of Cologne, Köln, Deutschland.
A
A
Engert
Department of Radiation Oncology, University of Muenster, Albert-Schweitzer Campus 1, Gebäude 1 A, 48419, Muenster, Germany. hans.eich@ukmuenster.de.
H T
HT
Eich
D005858:Germany / Q000453:epidemiology; D019983:Guideline Adherence / Q000592:standards / Q000706:statistics & numerical data*; D006689:Hodgkin Disease / Q000453:epidemiology* / Q000532:radiotherapy*; D006801:Humans; D017410:Practice Guidelines as Topic; D015995:Prevalence; D011785:Quality Assurance, Health Care / Q000706:statistics & numerical data*; D018787:Radiation Oncology / Q000592:standards*; D020266:Radiotherapy, Conformal / Q000592:standards* / Q000706:statistics & numerical data; D012307:Risk Factors; D018511:Systems Integration; D016896:Treatment Outcome
Intensity-modulated radiotherapy; Lymphoma; Organs at risk; Sequelae; Treatment failure
Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1173-80
19386423
Int J Radiat Oncol Biol Phys. 2015 May 1;92 (1):46-53
25863753
J Clin Oncol. 2010 Sep 20;28(27):4199-206
20713848
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):268-76
22079733
Strahlenther Onkol. 2014 Oct;190(11):1053-9
24972890
Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1578-86
19596171
J Clin Oncol. 2003 Oct 1;21(19):3601-8
12913100
Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):854-62
23790512
Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1419-24
18234433
Radiother Oncol. 2006 Jun;79(3):270-7
16797755
Lancet. 2012 May 12;379(9828):1791-9
22480758
Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):305-10
8892452
N Engl J Med. 2010 Aug 12;363(7):640-52
20818855
Strahlenther Onkol. 2008 Aug;184(8):406-10
18956517
Strahlenther Onkol. 2005 Sep;181(9):557-66
16170482
Strahlenther Onkol. 2015 Sep;191(9):717-25
25876905